Dr. Franklin AFINJUOMO completed his Ph.D. degree at the University of South AUSTRALIA with a research focus on the use of inulin as a drug delivery carrier. My PhD work involves the use of inulin microparticles as carriers to deliver drugs to immune cells. I also made significant contributions to the synthesis of new hydrogel from inulin polysaccharides and to how these materials can contribute to colon-targeting delivery
Franklin always had a passion for the development of novel drug delivery systems.
Franklin Afinjuomo’s primary research interests include drug delivery system, polysaccharides conjugates synthesis, characterization, and their biomedical applications. I have expertise in the area of novel formulation and product... Read more
About me
Dr. Franklin AFINJUOMO completed his Ph.D. degree at the University of South AUSTRALIA with a research focus on the use of inulin as a drug delivery carrier. My PhD work involves the use of inulin microparticles as carriers to deliver drugs to immune cells. I also made significant contributions to the synthesis of new hydrogel from inulin polysaccharides and to how these materials can contribute to colon-targeting delivery
Franklin always had a passion for the development of novel drug delivery systems.
Franklin Afinjuomo’s primary research interests include drug delivery system, polysaccharides conjugates synthesis, characterization, and their biomedical applications. I have expertise in the area of novel formulation and product development and reverse engineering of products
Expertise in the area
Hydrogel
Microparticles
Microsphere
Film-oral and vaginal films
Nanosystem
Analytical characterization using multiple techniques such as HPLC, FTIR, DSC, TGA, XRD, SEM, NMR
About me
Doctor of Philosophy University of South Australia
Graduate Diplima of Clinical Pharmacy University of Tasmania
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
Open access
3
3
3
|
2024 |
Open access
1
1
114
|
2023 |
29
27
8
|
2023 |
Open access
9
10
4
|
2023 |
Open access
4
|
2023 |
Open access
9
8
1
|
2023 |
Open access
8
7
2
|
2022 |
Open access
12
12
6
|
2022 |
Open access
15
13
6
|
2022 |
Open access
14
11
7
|
2021 |
Open access
34
28
4
|
2021 |
Open access
47
41
6
|
2021 |
Open access
19
18
1
|
2020 |
Open access
14
14
|
2020 |
Open access
10
9
1
|
2020 |
Open access
28
17
99
|
2019 |
Open access
19
18
2
|
2019 |
Open access
9
9
2
|
2019 |
Open access
52
45
|
2019 |
Open access
41
36
|
2019 |
Open access
24
23
3
|
External engagement & recognition
Organisation | Country |
---|---|
Advanced Veterinary Therapeutics | AUSTRALIA |
Chalmers University of Technology | SWEDEN |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
Neoculi Pty. Ltd. | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
The Queen Elizabeth Hospital | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
Vaxine Pty Ltd | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
MemberPharmaceutical Society of Botswana |
2020 |
MemberPharmaceutical Society of Australia |
2020 |
MemberPharmaceutical Society of Nigeria, Lagos Branch |
2020 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
Novel antimicrobials delivery systems for multi drug resistant infections | Current |
3D printed biodegradable films for targeted chemotherapy in liver cancer | Completed |